Nanjing Vazyme Biotech Co., Ltd. (688105.SS) Bundle
Ready to probe the financial pulse of Nanjing Vazyme Biotech Co., Ltd.? This deep-dive starts with hard numbers: in the quarter ended CNY 346.18 million (Sept 30, 2025), revenue rose 2.84% quarter-over-quarter while trailing twelve-month revenue sits at CNY 1.34 billion (down 4.15% year-over-year), contrasted with a full-year 2024 revenue of CNY 1.38 billion (+7.15% vs. 2023); profitability shows strain-TTM net profit margin is -1.31% with a nine-month net income of CNY 6.62 million (vs. CNY 18.16 million prior year) and EPS dropping to CNY 0.02-yet balance sheet strengths include a net cash position of CNY 1.82 billion and net cash per share of CNY 4.57 even as market valuation signals high expectations (P/S 6.46, forward P/E 107.68) and market cap moved between CNY 8.68 billion (stock CNY 21.83 on Dec 8, 2025) and CNY 8.19 billion (Dec 11, 2025); with a manageable debt-to-equity of ~27.95%, >$80M invested in R&D, global certifications and extensive R&D/manufacturing infrastructure, these contrasting metrics raise urgent questions for investors-read on to unpack revenue trends, margin pressures, cash resilience, valuation signals and the growth catalysts that could reshape the outlook
Nanjing Vazyme Biotech Co., Ltd. (688105.SS) - Revenue Analysis
Nanjing Vazyme Biotech reported CNY 346.18 million in revenue for the quarter ending September 30, 2025, up 2.84% sequentially. On a trailing twelve months (TTM) basis revenue is CNY 1.34 billion, a 4.15% decline year-over-year, while full-year 2024 revenue was CNY 1.38 billion, representing a 7.15% increase versus 2023.- Quarter (Q3 2025): CNY 346.18 million (+2.84% QoQ)
- TTM Revenue: CNY 1.34 billion (-4.15% YoY)
- FY 2024 Revenue: CNY 1.38 billion (+7.15% YoY vs. 2023)
- Revenue per employee: CNY 468,920 (2,867 employees)
- Market capitalization: CNY 8.68 billion; Stock price: CNY 21.83 (as of 2025-12-08)
- Price-to-sales (P/S) ratio: 6.46
| Metric | Value | Change |
|---|---|---|
| Q3 2025 Revenue | CNY 346.18 million | +2.84% QoQ |
| TTM Revenue | CNY 1.34 billion | -4.15% YoY |
| FY 2024 Revenue | CNY 1.38 billion | +7.15% YoY (2024 vs 2023) |
| Revenue per Employee | CNY 468,920 | 2,867 employees |
| Market Capitalization | CNY 8.68 billion | - |
| Share Price (2025-12-08) | CNY 21.83 | - |
| Price-to-Sales (P/S) | 6.46 | - |
- Growth dynamics: Sequential uptick in Q3 2025 suggests stabilization after TTM contraction; FY 2024 growth indicates past recovery momentum.
- Efficiency: Revenue per employee (~CNY 468.9k) provides a productivity benchmark versus peers in molecular diagnostics and biotech manufacturing.
- Valuation context: P/S of 6.46 and market cap of CNY 8.68 billion imply investor premium relative to current sales - important when assessing growth expectations and multiples.
- Investor focus areas: sustaining quarter-to-quarter revenue growth, reversing TTM decline, and translating R&D/commercial expansion into consistent top-line gains.
Nanjing Vazyme Biotech Co., Ltd. (688105.SS) - Profitability Metrics
Nanjing Vazyme Biotech's recent profitability profile shows pressure on earnings and returns through the most recent reporting periods. Key measures highlight shrinking net income, negative margins on a trailing basis, and modest per-share losses, while market-based forward valuation implies high expectations for a recovery.
- Net income (9 months to Sep 30, 2025): CNY 6.62 million, down from CNY 18.16 million in the same period of 2024.
- Basic EPS from continuing operations (9M 2025): CNY 0.02, versus CNY 0.05 in the prior year period.
- Loss per share (last 12 months): CNY 0.07.
| Metric | Value | Interpretation |
|---|---|---|
| TTM Net Profit Margin | -1.31% | Net loss relative to revenue across the trailing twelve months. |
| Return on Equity (ROE) | -0.86% | Negative return on shareholders' equity - capital not generating positive earnings. |
| Forward P/E | 107.68 | Market pricing implies expectation of materially higher future EPS; valuation is high versus current results. |
Investors assessing operational trends should consider the disconnect between current profitability and forward market expectations. For broader context on shareholder composition and investor behavior that may be influencing valuation, see Exploring Nanjing Vazyme Biotech Co., Ltd. Investor Profile: Who's Buying and Why?
Nanjing Vazyme Biotech Co., Ltd. (688105.SS) - Debt vs. Equity Structure
Nanjing Vazyme Biotech's balance between liabilities and owners' equity shows a conservative leverage profile with a clear cash surplus on the balance sheet. Key headline figures highlight debt-light capitalization and a net cash position that materially reduces financial risk while supporting operational flexibility.- Total debt: CNY 1.09 billion
- Equity (book value): CNY 3.90 billion
- Debt-to-equity ratio: ~27.95%
- Cash & cash equivalents: CNY 2.91 billion
- Net cash (cash - debt): CNY 1.82 billion
- Net cash per share: CNY 4.57
- Enterprise value: CNY 6.33 billion
- Market capitalization (as of 2025-12-11): CNY 8.19 billion
| Metric | Amount (CNY) | Notes / Calculation |
|---|---|---|
| Total Debt | 1,090,000,000 | Includes short- and long-term interest-bearing liabilities |
| Cash & Cash Equivalents | 2,910,000,000 | Reported on latest balance sheet |
| Net Cash | 1,820,000,000 | 2,910,000,000 - 1,090,000,000 |
| Equity (Book Value) | 3,900,000,000 | Total shareholders' equity |
| Debt-to-Equity Ratio | 27.95% | 1,090,000,000 ÷ 3,900,000,000 |
| Net Cash per Share | 4.57 | Net cash ÷ outstanding shares |
| Enterprise Value (EV) | 6,330,000,000 | Market cap + debt - cash |
| Market Capitalization | 8,190,000,000 | As of 2025-12-11 |
- Low leverage: the sub-30% debt-to-equity ratio indicates limited reliance on debt funding relative to equity.
- Positive liquidity cushion: net cash of CNY 1.82 billion provides buffer for R&D, capex, or opportunistic M&A.
- EV vs. Market Cap: enterprise value (CNY 6.33B) is below market cap (CNY 8.19B) due to the strong cash position, implying market valuation includes growth/earnings premia beyond simple enterprise fundamentals.
Nanjing Vazyme Biotech Co., Ltd. (688105.SS) Liquidity and Solvency
Nanjing Vazyme Biotech's balance sheet shows a strong cash position and moderate leverage. While standard short-term liquidity ratios (current ratio and quick ratio) are not specified in the available data, several disclosed metrics provide clear insight into the company's ability to meet obligations and its capital structure.
- Net cash position: CNY 1.82 billion - indicates the company holds more cash than short- and long-term debt on aggregate.
- Debt-to-equity ratio: ~27.95% - a moderate level of financial leverage.
- Enterprise value (EV): CNY 6.33 billion - reflects market valuation including debt and excluding cash.
- Net cash per share: CNY 4.57 - cash backing per outstanding share.
- Current ratio: Not specified in available data.
- Quick ratio: Not specified in available data.
| Metric | Value | Interpretation |
|---|---|---|
| Net Cash | CNY 1.82 billion | Net liquidity buffer available to fund operations, R&D, and strategic initiatives |
| Debt-to-Equity Ratio | 27.95% | Moderate leverage - manageable debt relative to shareholder equity |
| Enterprise Value (EV) | CNY 6.33 billion | Market valuation metric incorporating debt and excluding cash |
| Net Cash per Share | CNY 4.57 | Direct cash attributable to each outstanding share |
| Current Ratio | Not specified | Short-term liquidity measure unavailable |
| Quick Ratio | Not specified | Immediate liquidity excluding inventories unavailable |
For broader context on ownership, trading behaviour and investor composition relevant to these liquidity and solvency metrics, see: Exploring Nanjing Vazyme Biotech Co., Ltd. Investor Profile: Who's Buying and Why?
Nanjing Vazyme Biotech Co., Ltd. (688105.SS) - Valuation Analysis
Nanjing Vazyme Biotech Co., Ltd. (688105.SS) presents a valuation profile characterized by elevated market multiples and a solid cash position. Key headline metrics as of early December 2025 are summarized below and then analyzed in context.
- Price-to-Sales (P/S): 6.46 - market values each CNY 1 of sales at ~CNY 6.46.
- Forward P/E: 107.68 - high forward multiple implying strong growth expectations or low near-term earnings.
- Enterprise Value (EV): CNY 6.33 billion - reflects total firm value including debt, excluding cash.
- Market Capitalization: CNY 8.19 billion (as of December 11, 2025).
- Net Cash per Share: CNY 4.57 - indicates net cash available on a per-share basis.
- Share Price: CNY 21.83 (as of December 8, 2025).
| Metric | Value | Context / Unit |
|---|---|---|
| Price-to-Sales (P/S) | 6.46 | Times |
| Forward Price-to-Earnings (P/E) | 107.68 | Times (forward) |
| Enterprise Value (EV) | CNY 6.33 billion | Corporate valuation (ex-cash) |
| Market Capitalization | CNY 8.19 billion | As of Dec 11, 2025 |
| Net Cash per Share | CNY 4.57 | Per-share net cash |
| Share Price | CNY 21.83 | As of Dec 8, 2025 |
Implications for valuation and investor perspective:
- High P/S (6.46) suggests investors are paying a premium for revenue - typical for biotech firms with scalable products or strong IP.
- Extremely high forward P/E (107.68) signals that market earnings expectations are elevated; small absolute EPS can inflate this ratio, so sensitivity to earnings misses is high.
- EV (CNY 6.33B) below market cap (CNY 8.19B) combined with positive net cash per share (CNY 4.57) highlights a net cash balance sheet that de-risks EV relative to equity value.
- Net cash per share of CNY 4.57 reduces effective valuation for operating assets when converting market cap to cash-adjusted terms (i.e., equity value less net cash).
- Share price (CNY 21.83) relative to net cash implies a substantial portion of the quoted price is attributable to operating business expectations rather than just cash on the balance sheet.
Valuation sensitivities to monitor:
- Earnings realization vs. forward P/E - small changes in EPS materially alter the P/E and investor sentiment.
- Revenue growth trajectory relative to P/S multiple - whether sales growth justifies a 6.46x P/S.
- Changes in net cash (e.g., R&D spending, acquisitions, or capital returns) that shift EV and cash-adjusted equity value.
For corporate mission and strategic direction that underpin these valuation assumptions, see: Mission Statement, Vision, & Core Values (2026) of Nanjing Vazyme Biotech Co., Ltd.
Nanjing Vazyme Biotech Co., Ltd. (688105.SS) - Risk Factors
Nanjing Vazyme Biotech faces several measurable financial and market risks that investors should weigh carefully. Key metrics over the trailing twelve months and market data reveal vulnerabilities in profitability, shareholder returns, valuation, leverage, and market capitalization trends.- Profitability risk: Net profit margin (TTM) = -1.31%, indicating the company is operating at a net loss relative to revenue, which may constrain cash generation and reinvestment capacity.
- Shareholder return risk: Return on equity (ROE) = -0.86%, reflecting negative returns on equity and potential dilution of shareholder value if losses persist.
- Leverage risk: Debt-to-equity ≈ 27.95%, a moderate leverage level that can amplify stress on the balance sheet during revenue shortfalls or rising interest rates.
- Valuation risk: Forward P/E = 107.68, implying very high market expectations for future earnings growth; any earnings miss could trigger a sharp re-rating.
- Market capitalization decline: Market cap fell 16.32% over the past year, from CNY 9.38 billion to CNY 8.19 billion, signaling negative market sentiment or deteriorating outlook.
| Metric | Value | Implication |
|---|---|---|
| Net Profit Margin (TTM) | -1.31% | Operating at a net loss; weak profitability |
| Return on Equity (ROE) | -0.86% | Negative returns on shareholders' equity |
| Debt-to-Equity | 27.95% | Moderate leverage; manageable but sensitive to cash flow |
| Forward P/E | 107.68 | High valuation relative to forecasted earnings |
| Market Capitalization (1Y change) | CNY 9.38B → CNY 8.19B (-16.32%) | Market value erosion over the past 12 months |
- Operational sensitivity: With negative margins, any decline in revenue or increase in R&D/manufacturing costs can quickly widen losses and increase financing needs.
- Execution and clinical/regulatory risk: Biotech firms like Nanjing Vazyme depend on successful product development and regulatory approvals; setbacks can materially affect forward P/E justification.
- Financing and dilution risk: Continued losses increase the likelihood of equity or debt raises; given current ROE and market cap decline, new financing could be dilutive or expensive.
- Market-perception risk: High forward P/E despite negative TTM profitability suggests investor optimism; failure to meet growth expectations can lead to steep valuation corrections.
- Macro and interest-rate risk: Moderate leverage combined with potential tightening monetary conditions could raise interest costs and pressure free cash flow.
Context and corporate direction can be reviewed in the company's stated objectives: Mission Statement, Vision, & Core Values (2026) of Nanjing Vazyme Biotech Co., Ltd.
Nanjing Vazyme Biotech Co., Ltd. (688105.SS) Growth Opportunities
Nanjing Vazyme Biotech Co., Ltd. (688105.SS) demonstrates multiple vectors for scalable growth driven by sustained R&D investment, global market penetration, and substantial infrastructure capacity. Key headwinds and tailwinds center on innovation pipeline expansion, international market certifications, and a diversified talent base that supports commercial and scientific scaling.- R&D commitment: cumulative investment exceeding $80 million in projects, personnel, and equipment - enabling continued product development and platform enhancement.
- Global market access: 196 market-access certifications supporting distribution and regulatory compliance across more than 60 countries and regions.
- Talent and capabilities: a global R&D operation employing over 3,000 staff (scientists, experts, bio-technicians, medical specialists, engineers, software developers) to accelerate discovery-to-commercialization timelines.
- Scientific credibility: over 2,000 published papers worldwide, including more than 260 papers in Cell, Nature, Science and sub-journals (as of November 2021), reinforcing reputation and partnership potential.
- Infrastructure scale: a 25,000 m² R&D center paired with a 64,000 m² biological reagents and raw materials production base, supporting capacity expansion and potential margin improvement through scale.
- Strategic vision: a stated aim to lead in biotechnology through relentless innovation, high product/service quality standards, and customer value creation-positioning the company to capture adjacent markets and platform licensing opportunities.
| Metric | Value / Detail |
|---|---|
| Cumulative R&D Investment | $80,000,000+ |
| Market-access Certifications | 196 |
| Geographic Reach | Products/services in 60+ countries & regions |
| Global R&D & Staff | 3,000+ employees (scientists, technicians, engineers, etc.) |
| Academic Publications | 2,000+ papers (260+ in Cell/Nature/Science & sub-journals, as of Nov 2021) |
| R&D Facility Area | 25,000 m² |
| Production Base Area | 64,000 m² (biological reagents & raw materials) |
- Commercial growth drivers: leverage certifications and production scale to accelerate export volumes, expand reagent portfolio, and pursue higher-margin proprietary assays and platform services.
- Partnership and licensing runway: scientific publication footprint and global talent pool support collaborations with academic institutions, CROs, and pharmaceutical partners for co-development and licensing revenue streams.
- Operational leverage: large-scale production base provides potential cost advantages and faster time-to-market for novel reagents and diagnostic kits, improving gross-margin prospects as volumes rise.
- Risk-to-reward considerations: continued heavy R&D spending can compress near-term profitability but is positioned to drive differentiated products and IP that support long-term revenue growth and valuation upside.
Nanjing Vazyme Biotech Co., Ltd. (688105.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.